TFRC and cancer: developed endogenous human ferritin heavy-chain nanocages (HFn) to serve as the carrier of paclitaxel (PTX), which can specifically bind to blood-brain barrier and TFR1 widely overexpressed in glioma cells, and showed that HFn-PTX showed the best anti-tumor effect, and the median survival time was significantly longer than that of free PTX (207); additionally, doxorubicin-loaded ferritin heavy chain (DOX-FTH) can be taken up and induce apoptosis of cancer cells overexpressing TFR1 (208); and Cheng et al.